bioAffinity Technologies Inc (NASDAQ: BIAF) stock falls in Monday premarket. Investors weigh 2025 revenue declines against surging CyPath Lung sales.
Importance Rank:
1
bioAffinity Technologies Inc (NASDAQ: BIAF) stock falls in Monday premarket. Investors weigh 2025 revenue declines against surging CyPath Lung sales.